The global anti-vascular endothelial growth factor therapeutics market size is expected to be worth around US$ 14.80 billion by 2030, according to a new report by Vision Research Reports.
The global anti-vascular endothelial growth factor therapeutics market size was valued at US$ 13.67 billion in 2020 and is anticipated to grow at a CAGR of 0.8% during forecast period 2021 to 2030.
Get Sample Copy of This Report (Including TOC, List of Tables & Figures, and Chart)@ https://www.visionresearchreports.com/report/sample/38607
Anti-Vascular Endothelial Growth Factor Therapeutics Market (By Product: Eylea, Lucentis, Beovu; By Disease: Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, Age-related Macular Degeneration) – Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 2021 – 2030
|Market Size||USD 14.80 billion by 2030|
|Growth Rate||CAGR of 0.8% From 2021 to 2030|
|Historic Data||2017 to 2020|
|Forecast Period||2021 to 2030|
|Segments Covered||Product, Disease|
|Regional Scope||North America, Europe, Asia Pacific, Latin America, Middle East & Africa|
|Companies Mentioned||Regeneron Pharmaceuticals, Inc.; Bayer AG; Novartis AG; F. Hoffmann-La Roche Ltd.; Biogen; Pfizer, Inc.; CoherusBioSciences; Amgen, Inc.; Bausch Health Companies, Inc.; and Viatris, Inc.|
The anti-Vascular Endothelial Growth Factor (VEGF) therapeutics market growth can be attributed to an increase in the prevalence of ophthalmic diseases, such as macular edema, diabetic retinopathy, retinal vein occlusion, and Age-related Macular Degeneration (AMD), coupled with an increasing geriatric population that is exposed to the risk of developing the condition. According to the WHO, around 196 million people are affected by AMD globally, which includes over 10.4 million cases with moderate to severe vision impairment. In addition, product launches and research advancements are contributing to the market growth.
The Eylea product segment dominated the global market in 2020 with a revenue share of over 68%. The segment is anticipated to retain its dominance throughout the forecast period. The product is expected to witness significant demand owing to advancements in formulations and the development of advanced drug delivery systems.
This new formulation may increase product adoption by ophthalmologists due to its ease of administration. Beovuis anticipated to witness the fastest CAGR over the forecast period owing to geographic expansion and patent exclusivity.
The Age-related Macular Degeneration (AMD) segment accounted for the largest market share of more than 89% in 2020.The segment is expected to maintain the leading position over the forecast period owing to the increasing disease burden, growing geriatric population, and presence of late-stage product candidates that are expected to enter the market in the coming years.
North America region accounted for the highest revenue share of more than 66% of the global market in 2020. The regional market is expected to witness a significant growth rate over the forecast period. Factors
Such delivery systems with technological advancements and product launches are expected to positively impact the market growth in the region. Asia Pacific is expected to grow at the fastest CAGR of 2.8% from2021 and 2030.
- F. Hoffmann-La Roche Ltd.
- Pfizer, Inc.
- Amgen, Inc.
- Bausch Health Companies, Inc.
- Viatris, Inc.
- Macular Edema
- Diabetic Retinopathy
- Retinal Vein Occlusion
- Age-related Macular Degeneration
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
- Saudi Arabia
- South Africa
- North America
Buy This Premium Research Report, click here@ https://www.visionresearchreports.com/report/cart/38607 or call: +1 9197 992 333